Integration of Immunotherapies Into the Treatment of Patients With Non-Small Cell Lung Cancer

This CE/CME/CEU-accredited supplement is jointly provided by

Reports From the International Association for the Study of Lung Cancer (IASLC) 17th World Conference

December 4–7, 2016 Vienna, Austria

Release date: February 25, 2017
Expiration date: February 25, 2018
Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Drive, Dinah Shore Bldg. Rancho Mirage, CA 92270
Voice:  760-773-4500
Fax: 760-773-4513
E-mail:   contactce@annenberg.net

Estimated time to complete activity: 1.5 hours

The ASCO Post
94 North Woodhull Road Huntington, NY 11743
Voice:  631-692-0800
Fax: 631-692-0805
E-mail:   editor@harborsidepress.com

This supplement is supported by an independent educational grant from Merck.

Faculty

Michael Boyer, MBBS, PhD, Chief Clinical Officer and Conjoint Chair of Medical Oncology (Thoracic Oncology), Chris O’Brien Lifehouse, Sydney, Australia
Julie Renee Brahmer, MD, Interim Director and Associate Professor of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
Beth Eaby-Sandy, MSN, CRNP, OCN, nurse practitioner, University of Pennsylvania’s Abramson Cancer Center, Philadelphia
Shirish M. Gadgeel, MD, medical oncologist and leader of the Thoracic Oncology Multidisciplinary Team, Karmanos Cancer Center, Detroit
Marina C. Garassino, MD, Medical Director of the IRCCS Istituto Nazionale dei Tumori Foundation, Milan, Italy
Edward B. Garon, MD, Director of Thoracic Oncology, David Geffen School of Medicine, University of California, Los Angeles
Scott N. Gettinger, MD, Associate Professor of Medicine (Medical Oncology), Yale Cancer Center, New Haven, Connecticut
Roy S. Herbst, MD, PhD, Chief of Medical Oncology and Associate Director for Translational Research, Yale Cancer Center, New Haven, Connecticut
Paul Mitchell, MD, Associate Professor at the Olivia Newton-John Cancer and Wellness Centre, Melbourne, Australia
Solange Peters, MD, Professor and Chief of Medical Oncology, University of Lausanne, Switzerland
Claire F. Verschraegen, MD, Medical Director of Hematology and Oncology, University of Vermont Cancer Center, Burlington

Activity Rationale and Purpose

Safely and effectively incorporating new and emerging agents into existing regimens for the management of patients with advanced/metastatic non–small cell lung cancer (NSCLC) remains complex. The emergence of immunotherapy agents, notably checkpoint inhibitors, represents a paradigm shift in NSCLC therapy. This supplement to The ASCO Post will provide oncologists and other oncology professionals with state-of-the art information they need to effectively manage patients with NSCLC.

Intended Audience

The activity's target audience will consist of physicians, nurse practitioners, PAs, oncology and hematology nurses and pharmacists.

Learning Objectives

After completing this educational activity, participants should be able to:

  1. Demonstrate an increased understanding of the mechanism of action of targeted and immunotherapies in the treatment of NSCLC
  2. Identify data reviewed at IASLC World Conference on Lung Cancer about clinical trials related to immunotherapies in NSCLC
  3. Anticipate adverse events associated with the integration of immunotherapies in the treatment of NSCLC

Continuing Education

Statement of Credit—Participants who successfully complete this activity (including the submission of the post-test and evaluation form) will receive a statement of credit.

Physicians. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Harborside Medical Education. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses. Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
A maximum of 1.5 contact hours may be earned for successful completion of this activity.

Provider is approved by the California Board of Registered Nursing, Provider No. 13664, for 1.5 contact hours.

Pharmacists. The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program has been assigned ACPE Universal Program #0797-9999-17-023-H04-P. 
This program is designated for up to 1.5 contact hours (0.15 CEUs) of continuing pharmacy education credit.

Financial Disclosures

All individuals in positions to control the content of this program (eg, planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this continuing education activity. The Annenberg Center for Health Sciences at Eisenhower has identified and resolved all conflicts of interest in accordance with the Annenberg Center for Health Sciences at Eisenhower policies and procedures. Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity.

Disclosures

Michael Boyer, MBBS, PhD, has received research support from Genentech/Roche, Pfizer, Eli Lilly, Merck Sharpe and Dohme, AstraZeneca, and Clovis.
Julie Renee Brahmer, MD, has received research support from Bristol-Myers Squibb, Medimmune/AstraZeneca, and Merck and is a consultant for Bristol-Myers Squibb (uncompensated), Celgene, Eli Lilly, and Merck, the sponsor of KEYNOTE-024.
Beth Eaby-Sandy, MSN, CRNP, OCN, has served as a consultant to Ariad and is on the speakers bureaus for Amgen, Helsinn, and Merck.
Shirish M. Gadgeel, MD, is a consultant for Genentech/Roche, Pfizer, Bristol-Myers Squibb, Ariad, and AstraZeneca and is on the speakers bureau for Genentech/Roche and AstraZeneca.
Marina C. Garassino, MD, has received research support from Pfizer and is a consultant for AstraZeneca, Bristol-Myers Squibb, Celgene, Roche, Merck Sharp & Dohme, and Eli Lilly.
Edward B. Garon, MD, has received research support from AstraZeneca, Boehringer Ingelheim, Bristol- Myers Squibb, Eli Lilly, Merck, Mirati, Genentech, Pfizer, and Novartis.
Scott N. Gettinger, MD, has received institutional research funding and consulting fees from Bristol- Myers Squibb.
Roy S. Herbst, MD, PhD, has been a consultant to AstraZeneca, Eli Lilly, Merck, Pfizer, and Genentech/ Roche; has received clinical trials/grant support from Genentech and Merck.
Paul Mitchell, MD, is on the advisory boards of Bristol-Myers Squibb, Merck (MSD), AstraZeneca, Roche, and Celgene; has received travel grants from Bristol-Myers Squibb and Roche; and honoraria from Roche.
Solange Peters, MD, reported no potential conflicts of interest.
Claire F. Verschraegen, reported no potential conflicts of interest.

Annenberg Center for Health Sciences at Eisenhower

John Bayliss, VP, Business Development at the Annenberg Center for Health Sciences at Eisenhower, spouse is an employee of Amgen, Inc; all other staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Content Reviewers

James O. Armitage, MD, University of Nebraska Medical Center
Wendy Smith, RN, MSN, ACNP, AOCN®, Director, Interprofessional Education, Harborside Medical Education

Planners

Harborside Press and Harborside Medical Education staff have no potential conflicts of interest to disclose.

Disclaimer

This activity has been designed to provide continuing education that is focused on specific objectives. In selecting educational activities, clinicians should pay special attention to the relevance of those objectives and the application to their particular needs. The intent of all Annenberg Center for Health Sciences at Eisenhower educational opportunities is to provide learning that will improve patient care. Clinicians are encouraged to reflect on this activity and its applicability to their own patient population.
The opinions expressed in this activity are those of the faculty and reviewers and do not represent an endorsement by Annenberg Center for Health Sciences at Eisenhower of any specific therapeutics or approaches to diagnosis or patient management.

Product Disclosure

This educational activity may contain discussion of published as well as investigational uses of agents that are not approved by the U.S. Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product.

How to Earn Credit

Select the Start button to complete the learning assessment and evaluation.

Statement of Credit: Participants who successfully complete this activity (including scoring a minimum of 70% on the learning assessment) and complete and submit the evaluation form will be able to download a statement of credit.

Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit(s)™
  • 1.50 ACPE
  • 1.50 ANCC
  • 1.50 Attendance
Course opens: 
02/25/2017
Course expires: 
02/25/2018
Cost:
$0.00
Rating: 
1

Available Credit

  • 1.50 AMA PRA Category 1 Credit(s)™
  • 1.50 ACPE
  • 1.50 ANCC
  • 1.50 Attendance

Accreditation Period

Course opens: 
02/25/2017
Course expires: 
02/25/2018

Price

Cost:
$0.00
Please login or register to take this course.